Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tuna Mutis

Showing results (41-50 of 110) with videos related to

Pageof 11
Sort By:
The Journal of Experimental Medicine|November 13, 2008
Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysisRobbert M Spaapen, Henk M Lokhorst, Kelly van den Oudenalder, et al.
Blood Advances|April 22, 2021
Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myelomaHilma J van der Horst, Anne T Gelderloos, Martine E D Chamuleau, et al.
Haematologica|November 27, 2010
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabMichael S van der Veer, Michel de Weers, Berris van Kessel, et al.
European Journal of Haematology|March 31, 2016
Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institutionLaurens E Franssen, Reinier A P Raymakers, Arjan Buijs, et al.
Cancers|December 16, 2020
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive MalignanciesChristie P M Verkleij, Amy Jhatakia, Marloes E C Broekmans, et al.
Blood|November 1, 2003
Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapyRob M Verdijk, Antoinette Kloosterman, Jos Pool, et al.
British Journal of Haematology|December 21, 2004
A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distributionPenny A Holloway, Niels Kaldenhoven, Henriette M Kok-Schoemaker, et al.
Autophagy|March 14, 2013
Endosome-mediated autophagy: an unconventional MIIC-driven autophagic pathway operational in dendritic cellsVangelis Kondylis, Hezder E van Nispen Tot Pannerden, Suzanne van Dijk, et al.
International Immunology|September 15, 2007
TAP-inhibiting proteins US6, ICP47 and UL49.5 differentially affect minor and major histocompatibility antigen-specific recognition by cytotoxic T lymphocytesLiesbeth E M Oosten, Danijela Koppers-Lalic, Els Blokland, et al.
International Journal of Molecular Sciences|January 27, 2021
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple MyelomaRenée Poels, Esther Drent, Roeland Lameris, et al.
Pageof 11

Showing results (41-50 of 110) with videos related to

Sort By:
Pageof 11
The Journal of Experimental Medicine|November 13, 2008
Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysisRobbert M Spaapen, Henk M Lokhorst, Kelly van den Oudenalder, et al.
Blood Advances|April 22, 2021
Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myelomaHilma J van der Horst, Anne T Gelderloos, Martine E D Chamuleau, et al.
Haematologica|November 27, 2010
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabMichael S van der Veer, Michel de Weers, Berris van Kessel, et al.
European Journal of Haematology|March 31, 2016
Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institutionLaurens E Franssen, Reinier A P Raymakers, Arjan Buijs, et al.
Cancers|December 16, 2020
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive MalignanciesChristie P M Verkleij, Amy Jhatakia, Marloes E C Broekmans, et al.
Blood|November 1, 2003
Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapyRob M Verdijk, Antoinette Kloosterman, Jos Pool, et al.
British Journal of Haematology|December 21, 2004
A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distributionPenny A Holloway, Niels Kaldenhoven, Henriette M Kok-Schoemaker, et al.
Autophagy|March 14, 2013
Endosome-mediated autophagy: an unconventional MIIC-driven autophagic pathway operational in dendritic cellsVangelis Kondylis, Hezder E van Nispen Tot Pannerden, Suzanne van Dijk, et al.
International Immunology|September 15, 2007
TAP-inhibiting proteins US6, ICP47 and UL49.5 differentially affect minor and major histocompatibility antigen-specific recognition by cytotoxic T lymphocytesLiesbeth E M Oosten, Danijela Koppers-Lalic, Els Blokland, et al.
International Journal of Molecular Sciences|January 27, 2021
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple MyelomaRenée Poels, Esther Drent, Roeland Lameris, et al.
Pageof 11